What question did this study set out to answer?

Compare 1-year changes in weight, body mass index, glycated hemoglobin, and healthcare resource utilization between adults initiating once-weekly semaglutide versus SGLT2 inhibitors in routine clinical practice.

March 27, 2025Diabetes TherapyOpen Access

Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

View Full Paper

Ask AI

Bookmark

Compare 1-year changes in weight, body mass index, glycated hemoglobin, and healthcare resource utilization between adults initiating once-weekly semaglutide versus SGLT2 inhibitors in routine clinical practice.
Conducted an observational cohort study using linked claims and electronic medical records (January 2018–February 2022) of adults with uncontrolled type 2 diabetes (HbA1c ≥ 7.0%).
Evaluated an overall once-weekly semaglutide cohort (N=772) alongside adherence/dose subgroups, and applied inverse probability of treatment weighting to compare semaglutide (N=416) with SGLT2 inhibitors (N=1093) at 1 year.
The full once-weekly semaglutide cohort (N=772) experienced significant 1-year mean reductions from baseline in weight (−4.4 kg), BMI (−1.5 kg/m²), and HbA1c (−1.5%) (all P < 0.0001).
In weighted comparisons, semaglutide demonstrated significantly greater 1-year reductions versus SGLT2 inhibitors in weight (−4.4 vs −3.4 kg, P = 0.0061), BMI (−1.5 vs −1.1 kg/m², P = 0.0013), and HbA1c (−1.6 vs −1.2%, P < 0.0001).
All-cause healthcare resource utilization after 1 year was similar between the weighted semaglutide and SGLT2 inhibitor cohorts.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational study shows greater reductions in weight and HbA1c with once-weekly semaglutide versus SGLT2 inhibitors in type 2 diabetes, indicating enhanced real-world clinical effectiveness.

Cite This Study

AMAMOO et al. (2025) studied this question.

synapsesocial.com/papers/6a73a31e7af34f94aaa7352b https://doi.org/10.1007/s13300-025-01721-y

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows greater reductions in weight and HbA1c with once-weekly semaglutide versus SGLT2 inhibitors in type 2 diabetes, indicating enhanced real-world clinical effectiveness.

Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

Key Points

Discussion

Implication

Cite This Study

Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider